ACE-083 is known as a follistatin-based therapeutic which binds to myostatin, along with other regulators of muscle . In addition, ACE-083 belongs to the TGF-β superfamily and is administered as a local injection to increase muscle mass and strength . ACE-083 is currently in clinical trials stages awaiting more data to confirm its therapeutic potential in certain human diseases. Currently, ACE-083 is being assessed and evaluated for its therapeutic role in skeletal muscle growth.
Figure 1. ACE-83 works by binding ligands such as myostatin (GDF8) and other factors and molecules which work by inhibiting skeletal muscle growth .
How it works
ACE-083 is known as a follistatin-based therapeutic . Follistatin has been described as a protein which inhibits follicle-stimulating hormone release . Specifically, ACE-083 works by binding to activin and myostatin and inhibiting their signalling . Activin and myostatin belong to a protein superfamily which are responsible for playing roles in regulating skeletal muscle mass .